1421693-22-2

Basic information

• Product Name: CDKI-73
• Synonyms: CDKI-73
• CAS NO: 1421693-22-2
• Molecular Formula: C₁₅H₁₅FN₆O₂S₂
• Molecular Weight: 394.4470032
• Mol File: 1421693-22-2.mol

Chemical Properties

• Boiling Point: 642.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.524±0.06 g/cm3(Predicted)
• PKA: 10.06±0.60(Predicted)
• CAS DataBase Reference: CDKI-73(CAS DataBase Reference)
• NIST Chemistry Reference: CDKI-73(1421693-22-2)
• EPA Substance Registry System: CDKI-73(1421693-22-2)

Safety Data

• Hazardous Substances Data: 1421693-22-2(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
CDKI-73 is used as a CDK9 inhibitor for the treatment of acute myeloid leukemia (AML). It has shown to be highly efficacious in targeting CDK9, which plays a critical role in the development and progression of AML. By inhibiting CDK9, CDKI-73 can potentially disrupt the abnormal cell cycle and proliferation of leukemia cells, leading to the suppression of tumor growth and improved patient outcomes.
Used in Drug Development:
In the pharmaceutical industry, CDKI-73 is used as a lead compound for the development of novel CDK inhibitors. Its potent activity against CDK9 makes it a valuable starting point for designing and synthesizing new drugs that can target various types of cancer, including solid tumors and hematological malignancies. The development of CDK inhibitors like CDKI-73 can lead to the creation of more effective and targeted cancer therapies with fewer side effects compared to conventional chemotherapy.
Used in Research:
CDKI-73 is also used as a research tool in the field of cell biology and oncology. It can be employed to study the role of CDK9 in various cellular processes, such as transcription, cell cycle regulation, and apoptosis. By understanding the molecular mechanisms underlying the action of CDKI-73, researchers can gain valuable insights into the development of cancer and the potential therapeutic strategies for its treatment.

Upstream product

• 98-18-0 m-aminobenzenesulfonamide 
• 2161-68-4 N,4-dimethyl-1,3-thiazol-2-amine 
• 878890-10-9 5-bromo-N,4-dimethylthiazol-2-amine 
• 4431-64-5 3-guanidinobenzenesulfonamide 
• 1421693-03-9 3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)-thiazol-5-yl)prop-2-en-1-one 
• 94284-66-9 2-methylamino-4-methyl-5-acetylthiazole 
• 364334-95-2 3-(dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one 

Relevant articles and documents

A method for preparing such CDK inhibitors (by machine translation)

The invention discloses a method for preparing such CDK inhibitors, will be single-methyl thiourea and 1 - N monochloride reaction, 4 - dimethylthiazole - 2 - amine, by bromo reaction to obtain 5 - bromo - N, 4 - dimethylthiazole - 2 - amine, under the action of the catalyst after the with the borate to obtain aromatic borate intermediates; aromatic borate ester intermediate with 2, 4 - dichloro - 5 fluoro uracil in the noble metal catalytic under suzuki coupling reaction to obtain the coupling product to continue after the Buchwald - Hartwig with the aromatic amine in the reaction, ultimately to obtain the target product. (by machine translation)

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from —SO2NH2, —SO2NHMe or —SO2NMe2, —SO2NHEt, or —SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from –SO2NH2, -SO2NHMe or –SO2NMe2, -SO2NHEt, or -SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.

Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities

Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B- and T-cells.